Trials / Terminated
TerminatedNCT01891669
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
A PHASE 1, DOSE ESCALATION STUDY OF PF-06263507 IN PATIENTS WITH ADVANCED SOLID TUMORS
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06263507 | Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined. |
| DRUG | PF-06263507 | Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1. |
Timeline
- Start date
- 2013-08-08
- Primary completion
- 2015-06-29
- Completion
- 2015-06-29
- First posted
- 2013-07-03
- Last updated
- 2019-01-09
- Results posted
- 2016-06-24
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01891669. Inclusion in this directory is not an endorsement.